Pharmaceutical company Haleon has recently issued a voluntary recall of two popular Robitussin cough medicines, namely Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult.
The recall comes in response to concerns about microbial contamination, raising potential health risks for consumers (via NBC News).
Potential Health Risks
The recall targets explicitly eight lots of cough syrups, with Haleon stating that no adverse effects have been reported thus far. However, the company has highlighted the potential severity of the issue, particularly for immunocompromised people.
Using these items may result in severe or life-threatening adverse events, such as fungemia or disseminated fungal infection. Non-immunocompromised consumers, on the other hand, are thought to be at a low risk of life-threatening infections. Still, the possibility of an infection requiring medical intervention cannot be completely ruled out.
Read Also : Ireland Secures Access to World's Costliest Drug, Bringing Hope to Children Battling Rare Disease
FDA Involvement
Haleon is taking proactive measures by notifying distributors and customers directly about the recall. The company urges consumers who have purchased the recalled cough syrups to cease consumption immediately and return the products.
Importantly, this recall is being conducted in collaboration with the US Food and Drug Administration (FDA), indicating a concerted effort to address the potential health risks of the contaminated cough syrups.
Robitussin Honey CF Max Day and Nighttime are popular cough syrups designed to temporarily relieve symptoms associated with cold or flu, hay fever, or other respiratory allergies.
The recall notice underscores the importance of consumers contacting their physicians or healthcare providers if they have experienced problems using these products.
Report to FDA
For consumers with concerns or questions, Haleon has provided contact information for their Consumer Relations team, reachable via phone at +1-800-245-1040 or email at mystory.us@haleon.com.
Additionally, the company emphasizes consumers' role in reporting adverse reactions or quality problems to the FDA's MedWatch Adverse Event Reporting program.
While the recall highlights the potential risks associated with microbial contamination in the affected cough syrups, it is essential to note that no adverse events have been reported.
In Other News
Ireland has secured access to Libmeldy, the world's most expensive drug. This development brings hope to children fighting against Metachromatic leukodystrophy (MLD), a rare and life-threatening inherited disease.
This drug developed by Orchard Therapeutics is poised to bring about a substantial positive change in the lives of affected children. This achievement comes after successful negotiations and collaboration with Belgium and the Netherlands.
Libmeldy, initially priced at a staggering €2.8 million (over US$ 3 million) for a one-off dose, is developed to treat MLD. This condition severely impacts the metabolic systems of children, leading to severe damage to the brain and nervous system.
Stay posted here at Tech Times.
